{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-040209","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.546577+00:00","generated_at":"2026-06-26T13:37:40.880328+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avenue Therapeutics CEO Lucy Lu resigns; COO David Jin becomes interim principal executive officer","bullets":["Lucy Lu, M.D. resigned as President, CEO, and Board member effective March 31, 2022, to pursue an outside opportunity.","She entered into a consulting arrangement with the Company effective March 31, 2022.","David Jin, previously COO, will serve as interim principal executive officer from March 31, 2022.","Company continues evaluating potential strategic transaction options."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-040209","json":"https://secwatch.observer/filing/0001104659-22-040209.json","markdown":"https://secwatch.observer/filing/0001104659-22-040209.md","text":"https://secwatch.observer/filing/0001104659-22-040209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/tm2210898d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T13:37:40.880328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d08f426d4","claim":"David Jin was appointed as interim principal executive officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"David Jin, who was previously serving as the Company’s Chief Operating Officer, will begin acting as the Company’s interim principal executive officer as of March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal executive officer"}],"fact_type":"executive_change"},{"claim_id":"c0a6cf6426","claim":"Lucy Lu resigned as President and Chief Executive Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"Lucy Lu, M.D. notified Avenue Therapeutics, Inc. (the “Company”) that she was resigning from her role as the Company’s President and Chief Executive Officer, and from her position as a member of the Company’s Board of Directors, effective in each case as of March 31, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}